Intuitive Surgical's ISRG Ion platform saw a 52% year-over-year increase in procedures to around 35,000 in the second quarter of 2025, with its first commercial procedures in Australia and Korea. The installed base grew to 905 systems, while capital placements declined to 54 from 74 in the prior year, indicating challenges in hardware sales despite rising utilization by 8%. The company's forward price-to-sales ratio is 16.13, above the industry average but below its five-year median of 26.91, and it carries a Value Score of D and Zacks Rank #3 (Hold). Stryker introduced its Mako 4 robotic system with FDA-cleared hip revision capability, and Globus Medical showcased its ExcelsiusFlex robotic navigation system for total knee arthroplasty, highlighting advancements in robotic surgical platforms.

Intuitive Surgical's ISRG Ion platform saw a 52% year-over-year increase in procedures to approximately 35,000 in the second quarter of 2025, highlighting strong utilization and expansion into new markets including Australia and Korea. While the installed base grew to 905 systems, capital placements declined to 54 from 74 in the prior year, indicating challenges in hardware sales despite improved patient engagement. The platform is positioned to transform early lung cancer diagnosis and thoracic procedures, drawing comparisons to the da Vinci system's early success. Stryker introduced its Mako 4 robotic system with FDA-cleared hip revision capabilities, while Globus Medical launched ExcelsiusFlex for total knee arthroplasty. Intuitive Surgical trades at a forward price-to-sales ratio of 16.13, below its five-year median of 26.91, with a Value Score of D and a Zacks Rank of #3 (Hold).

The global arthroscopy device market is projected to grow from USD 7.98 billion in 2024 to USD 12.85 billion by 2034, at a CAGR of 4.9%. Driven by rising orthopedic conditions, sports-related injuries, and advancements in minimally invasive surgical technologies, demand is increasing, particularly in North America and East Asia. Key players including Arthrex, Stryker, and Zimmer Biomet dominate the market through innovation, strategic acquisitions, and product development. The hospital segment is the largest end-user, with arthroscopic implants and visualization systems showing strong growth. Challenges such as high costs, regulatory hurdles, and product recalls remain, prompting companies to focus on cost-effective solutions and strategic partnerships.

The article identifies four GARP (Growth at a Reasonable Price) stocks—Ralph Lauren (RL), Stryker (SYK), Royal Gold (RGLD), and Autodesk (ADSK)—that meet specific investment criteria including strong earnings growth, return on equity above the industry average, and undervalued price-to-earnings and price-to-book ratios. Each stock is evaluated based on fundamental metrics such as earnings growth, ROE, P/E and P/B ratios, and Zacks Rank. The article highlights key business developments, such as Ralph Lauren's digital transformation and real estate investments, Stryker's AI-driven surgical technologies and product expansions, Royal Gold's acquisition plans for Sandstorm Gold and Horizon Copper, and Autodesk's growth in cloud-based design software. The stocks are projected to deliver solid returns in the near term, with performance metrics including year-to-date returns and trailing earnings surprises provided.

HTF Market Intelligence has published a comprehensive global study on the blood clot retrieval devices market, projecting it to grow at a compound annual growth rate (CAGR) of 13.6% from 2025 to 2032, reaching USD 2.017 billion by 2032, starting from USD 0.727 billion in 2025. The market is driven by rising thrombosis rates, advancements in minimally invasive technology, and expanding healthcare infrastructure, particularly in emerging regions. Key players include Boston Scientific, Bayer Healthcare, Medtronic, Argon Medical Devices, Teleflex, Penumbra, AngioDynamics, Johnson & Johnson, Terumo, ECKOS Corporation, Inari Medical, Stryker, GE Healthcare, Siemens Healthineers, Philips, MicroVention, Rapid Medical, Acandis, Phenox, and Valiant Labs. The market is segmented by device type and application, with North America leading currently and the Asia-Pacific region showing the fastest growth. Major trends include adoption of imaging-guided devices, portable operating theatres, and workflow-optimized endovascular suites. Challenges include high device costs, regulatory complexity, and a shortage of trained neuro-interventionists. Opportunities include developing lower-cost flexible devices, partnering with tele-stroke networks, and launching training programs in emerging markets. The report includes a Five Forces and PESTLE analysis to assess market dynamics and provides insights for strategic decision-making.